


The 1st Choice after AVF

When a viable AV fistula cannot be constructed, there's a need for a good alternative. There are important issues in choosing an alternative. How long will the access last before revision is required? How well will it respond to revision? What is the risk of infection occurring? How easy will it be for the dialysis staff to use the access?

Omniflow II provides a biosynthetic solution to these challenges, delivering reliable access with ease of handling. Clinical evidence and clinical experience make Omniflow II the 1st choice after AVF.


RELIABLE ACCESS



High Primary Patency

- means more time to the first revision


Omniflow studies^{1,2,3,4,5} show high primary patency, with a study versus PTFE showing rate at 2 years of 48% for Omniflow compared with 24% for PTFE.¹



High Secondary Patency

- means more time after revision

A study versus PTFE shows rate at 2 years of 58% for Omniflow compared to 47% to PTFE.¹



Low Infection Rate

- means more time without complications

Omniflow II demonstrates a low infection rate⁷ with a study showing a 2% frequency of infections in Omniflow patients compared with 10% for PTFE.¹

RELIABLE ACCESS – BY DESIGN

Resistance to Venous Anastomotic Hyperplasia


Good compliance⁶


Responds Well to Revision

Smooth flow surface

Resistance to Infection

Biocompatibility encourages rapid integration into host tissue. The associated micro-vascularisation of the Omniflow wall contributes to infection resistance.





EASE OF HANDLING


Cuts, Shapes & Trims With Ease
Preformed Loop Prevents Kinking

Minimal Suture Hole Bleeding
Minimal Seroma Formation
Ease of Puncturing
Rapid Haemostasis after Puncturing



Omniflow II's biosynthetic technology allows for ease of handling at implant and during dialysis. The fibrillar collagen structure of the Omniflow II wall provides self-sealing after puncturing.

THE OMNIFLOW II BIOSYNTHETIC TECHNOLOGY



Cross section of Omniflow II

Bio Nova has more than 25 years of clinical experience with biosynthetic vascular technology with over 100 technical publications and presentations culminating in the unique biosynthetic product Omniflow II.

Omniflow II is a composite structure of cross-linked ovine collagen with a polyester mesh endoskeleton. The polyester mesh provides strength and durability while the collagen structure is biocompatible which encourages rapid incorporation into host tissue. The collagen is stabilised, non-antigenic and remains structurally intact many years after implantation.

The Omniflow II wall is impervious to tissue in-growth and the flow surface is pre-healed and haemocompatible.

This biosynthetic technology makes Omniflow II the 1st choice after AVF.


PRODUCT RANGE

Omniflow™ II Vascular Prosthesis – Straight
For straight arteriovenous access

Catalogue numbers	Internal diameter		
Minimum length	5mm	6mm	8mm
35 cm	751-535	751-635	751-835
20 cm	751-520	751-620	751-820

Omniflow™ II Vascular Prosthesis – Curved
For looped arteriovenous access

Catalogue numbers	Internal diameter	
Minimum length	6mm	8mm
45 cm	741-645	741-845
40 cm	741-640	741-840
35 cm	741-635	741-835
30 cm	741-630	741-830



REFERENCES

1. Enzler M et al. Long term function of vascular access for hemodialysis. Clinical Transplantation 1996; 1:511-515.
2. Berardinelli L et al. Better Patency, lower rate of infection and of steal syndrome in HD-vascular access grafts made using biological / semi-biological materials. Presentation to the Vascular Access Society of America, Orlando 2008.
3. Palumbo P et al. Evaluation of Omniflow II Biosynthetic prosthesis for vascular access in haemodialysis patients: midterm results. Presentation to American Society of Nephrology, San Diego, 2006.
4. Wang S and Chu S. Clinical Use of Omniflow Vascular graft as Arteriovenous Bridging graft for hemodialysis. Artificial Organs 1996; 20: 1278-1281.
5. Ukovich L et al. Omniflow II prosthesis used for haemodialysis access: short term results. Abstract in Italian Journal of Vascular and Endovascular Surgery 2008; 15 (Suppl 1): 91.
6. Ramshaw J et al. Tissue-polymer composite vascular prostheses. Biomaterials and Bioengineering. 1995 Part B; Volume 2; 953-978.
7. Berardinelli L. The endless history of vascular access: a surgeon's perspective. Journal of Vascular Access 2006; 7:103-111.

DISTRIBUTOR DETAILS



bio nova

Bio Nova International Pty Ltd, North Melbourne, Victoria 3051, AUSTRALIA
www.bionova.com.au T +61 3 9326 6955 F +61 3 9329 8071 BN 9-8.5(0)-1